Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03432364 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
A Phase 1 study of Transfusion-dependent Beta-Thalassemia, sponsored by Sangamo Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 6
- Study locations
NCT03432364 is a Phase 1 study of Transfusion-dependent Beta-Thalassemia that has completed, run by Sangamo Therapeutics. The registered enrollment target is 5 participants, below the 111-participant average among 3 other Transfusion-dependent Beta-Thalassemia trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT03432364, a Phase 1 study of Transfusion-dependent Beta-Thalassemia, has completed, sponsored by Sangamo Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a single-arm, multi-site, single-dose, Phase 1/2 study to assess ST-400 in 6 subjects with transfusion-dependent β-thalassemia (TDT) who are ≥18 and ≤40 years of age. ST-400 is a type of investigational therapy that consists of gene edited cells. ST-400 is composed of the patient's own blood stem cells which are genetically modified in the laboratory using Sangamo's zinc finger nuclease (ZFN) technology to disrupt a precise and specific sequence of the enhancer of the BCL11A gene (which normally suppresses fetal hemoglobin production in erythrocytes). This process is intended to boost fetal hemoglobin (HbF), which can substitute for reduced or absent adult (defective) hemoglobin. ST-400 is then infused back into the patient after receiving conditioning chemotherapy to make room for the new cells in the bone marrow, with the aim of producing new erythrocytes with increased amounts of HbF. The primary objective is to understand safety and tolerability of ST-400, and secondary objectives are to assess the effects on HbF levels and transfusion requirements.
Conditions Studied
Interventions
- GENETIC ST-400 Investigational product
Study Locations (6)
California
- University of California, Los Angeles - Los Angeles
- UCSF Benioff Children's Hospital Oakland - Oakland
Georgia
- Children's Healthcare of Atlanta - Atlanta
Massachusetts
- Dana-Farber Boston Children's Cancer and Blood Disorders Center - Boston
Minnesota
- University of Minnesota - Minneapolis
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2022-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03432364
The ClinicalTrials.gov registry entry for NCT03432364 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 3 other Transfusion-dependent Beta-Thalassemia trials with a reported enrollment target (95% lower). The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transfusion-dependent Beta-Thalassemia appearing as the primary indexed condition, and to 1 intervention - of which ST-400 Investigational product is the first listed.
NCT03432364 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03432364 about?
NCT03432364 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)". This is a single-arm, multi-site, single-dose, Phase 1/2 study to assess ST-400 in 6 subjects with transfusion-dependent β-thalassemia (TDT) who are ≥18 and ≤40 years of age. ST-400 is a type of investigational therapy that consists of gene edited cells. ST-400 is composed of the patient's own blood...
What is the current status of trial NCT03432364?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-03-29. Estimated completion is 2022-11-17.
What conditions does trial NCT03432364 study?
This clinical trial studies the following conditions: Transfusion-dependent Beta-Thalassemia.
What interventions are being tested in trial NCT03432364?
The interventions under investigation include: ST-400 Investigational product (GENETIC).
Who is sponsoring clinical trial NCT03432364?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03432364 being conducted?
This trial has 6 study locations across California, Georgia, Massachusetts, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transfusion-dependent Beta-Thalassemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.